Detalles de la búsqueda
1.
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
BMC Cancer
; 22(1): 147, 2022 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35123422
2.
Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry.
Br J Haematol
; 193(1): 119-124, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32515050
3.
Comparing neuropathy in multiple myeloma and AL amyloidosis.
J Peripher Nerv Syst
; 26(1): 75-82, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33368817
4.
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Haematologica
; 105(6): 1650-1659, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31515355
5.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 374(17): 1621-34, 2016 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27119237
6.
Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study.
Eur J Haematol
; 102(2): 182-190, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30485563
7.
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
N Engl J Med
; 373(13): 1207-19, 2015 Sep 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-26308596
8.
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Blood
; 128(14): 1821-1828, 2016 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27531679
9.
Risk factors for blood stream infections in multiple myeloma: A population-based study of 1154 patients in Denmark.
Eur J Haematol
; 101(1): 21-27, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29569379
10.
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Am J Hematol
; 2018 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29726031
11.
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.
Haematologica
; 102(10): 1767-1775, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28751562
12.
Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
Eur J Haematol
; 97(3): 303-9, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26710662
13.
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biol Blood Marrow Transplant
; 21(12): 2039-2051, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26428082
14.
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.
Blood
; 121(23): 4647-54, 2013 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23616624
15.
Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival.
Eur J Haematol
; 94(1): 60-6, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24954766
16.
Characteristics and long-term outcome of patients with systemic immunoglobulin light-chain amyloidosis.
Acta Haematol
; 133(4): 336-46, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25531398
17.
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.
Acta Haematol
; 133(4): 372-380, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25824293
18.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol
; 15(11): 1195-206, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25242045
19.
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Am J Hematol
; 89(4): 355-62, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24273190
20.
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
Blood
; 118(5): 1239-47, 2011 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-21670471